Galenica


FY 2019 sales trump expectations, EBIT guidance upgraded

22/01/20 -"Galenica reported FY 19 sales of CHF 3.3bn, +4.3%, with broad-based growth across segments – services +2.9% to CHF 2.4bn and ‘health & beauty’ segment, +6.3%, to CHF 1.6bn. Management now ..."

Pages
39
Language
English
Published on
22/01/20
You may also be interested by these reports :
24/02/20
Sales missed expectations in Q3 due to the delay in installations of linacs in the US. Order intake was also weak with the US being the main drag. ...

21/02/20
Smith & Nephew reported good Q4/FY 19 numbers – trumping estimates. Q4/FY 19 sales were up 5.6%/4.4% on an underlying basis – driven by broad-based ...

20/02/20
We have not become more enthusiastic, but the inclusion of FMC’s better than expected performance has caused the increase in the EPS. The moderate ...

20/02/20
We have not become more enthusiastic, but the inclusion of the preliminary figures has caused the increase in the EPS. However, the quite colourless ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO